GENMAB AS SP.ADR/1/10DK 1 Market Cap ($15.06 Billion)
Market Cap & Net Worth: GENMAB AS SP.ADR/1/10DK 1 (GE91)
GENMAB AS SP.ADR/1/10DK 1 market cap. GENMAB AS SP.ADR/1/10DK 1 (F:GE91) has a market capitalization of $15.06 Billion (€12.88 Billion) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #1574 globally and #352 in its home market, demonstrating a -2.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENMAB AS SP.ADR/1/10DK 1's stock price €23.80 by its total outstanding shares 615993070 (615.99 Million). Also see cash flow conversion of GENMAB AS SP.ADR/1/10DK 1 for how efficiently the company converts equity into cash flow.
GENMAB AS SP.ADR/1/10DK 1 Market Cap History (2020–2026)
GENMAB AS SP.ADR/1/10DK 1 market cap history from 2020 to 2026. Data shows change from $23.21 Billion to $36.01 Billion (-2.39% CAGR). Check GENMAB AS SP.ADR/1/10DK 1 (GE91) stock price for real-time trading data and today's change.
GENMAB AS SP.ADR/1/10DK 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENMAB AS SP.ADR/1/10DK 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GE91 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.30x
GENMAB AS SP.ADR/1/10DK 1's market cap is 5.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.49x
GENMAB AS SP.ADR/1/10DK 1's market cap is 20.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $25.21 Billion | $1.28 Billion | $450.16 Million | 19.67x | 55.99x |
| 2022 | $28.66 Billion | $2.09 Billion | $784.70 Million | 13.73x | 36.53x |
| 2023 | $20.74 Billion | $2.39 Billion | $631.00 Million | 8.68x | 32.87x |
| 2024 | $14.40 Billion | $3.12 Billion | $1.13 Billion | 4.61x | 12.71x |
| 2025 | $19.73 Billion | $3.72 Billion | $963.00 Million | 5.30x | 20.49x |
Competitor Companies of GE91 by Market Capitalization
Companies near GENMAB AS SP.ADR/1/10DK 1 in the global market cap rankings as of November 1, 2026. Also see total assets of GENMAB AS SP.ADR/1/10DK 1 for a full breakdown of the balance sheet.
Key companies related to GENMAB AS SP.ADR/1/10DK 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of GENMAB AS SP.ADR/1/10DK 1 (2020–2026)
Market capitalization of GENMAB AS SP.ADR/1/10DK 1 from 2020 to today. Between 2020 and today, GENMAB AS SP.ADR/1/10DK 1's market cap moved from $23.21 Billion to $ 36.01 Billion, with a yearly change of -2.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €36.01 Billion | +82.48% |
| 2025 | €19.73 Billion | +37.00% |
| 2024 | €14.40 Billion | -30.56% |
| 2023 | €20.74 Billion | -27.64% |
| 2022 | €28.66 Billion | +13.71% |
| 2021 | €25.21 Billion | +8.59% |
| 2020 | €23.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GENMAB AS SP.ADR/1/10DK 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.06 Billion USD |
| MoneyControl | $15.06 Billion USD |
| MarketWatch | $15.06 Billion USD |
| marketcap.company | $15.06 Billion USD |
| Reuters | $15.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more